IVERIC bio

IVERIC bio Stock-Based Compensation

Delisted

The Stock-Based Compensation (SBC) of IVERIC bio (ISEE) as of Oct 22, 2026 is 26.68 M USD. In the previous year, Stock-Based Compensation (SBC) was 11.25 M USD — a change of 137.23% (higher).

Stock-Based Compensation

26.68 MUSD

YoY

137.23%

Last updated:

Stock-Based Compensation (SBC) of IVERIC bio is 2022 26.68 M USD. Stock-Based Compensation (SBC) of IVERIC bio was 2021 11.25 M USD. It decreases by 137.23% higher compared to the previous year.

The IVERIC bio Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2015
24.76 M USD
Jan 1, 2016
31.66 M USD
Jan 1, 2017
18.17 M USD
Jan 1, 2018
11.07 M USD
Jan 1, 2019
9.18 M USD
Jan 1, 2020
8.32 M USD
Jan 1, 2021
11.25 M USD
Jan 1, 2022
26.68 M USD
The IVERIC bio Stock-Based Compensation history
YEARStock-Based CompensationYoY
26.68 MUSD+137.23%
11.25 MUSD+35.11%
8.32 MUSD-9.34%
9.18 MUSD-17.09%
11.07 MUSD-39.07%
18.17 MUSD-42.61%
31.66 MUSD+27.87%
24.76 MUSD+89.88%
13.04 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVERIC bio stock

Stock-Based Compensation (SBC) of IVERIC bio is 26.68 M USD in 2022.

Stock-Based Compensation (SBC) of IVERIC bio changed from 11.25 M USD to 26.68 M USD, representing a 137.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) IVERIC bio since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s IVERIC bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IVERIC bio

All Key Metrics — IVERIC bio